Skelton Laurence Matthew
Known title: Chief Commercial OfficerCIK: 0002108080
Associated companies
Transaction History
| VERA | ▼ Sell | Open Market | 1,582 | $66K | 2/23/2026 | View on chart |
| VERA | ▲ Buy | Grant | 20,000 | $0 | 2/4/2026 | View on chart |
| VERA | ▼ Sell | Open Market | 1,582 | $66K | 2/23/2026 | View on chart |
| VERA | ▲ Buy | Grant | 20,000 | $0 | 2/4/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Leerink Partners Covers Vera Therapeutics at $34 Target
Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.
Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.